A China-based VC focused exclusively on the biotech industry combines a deep understanding of drug development, industry networks, as well as regulatory expertise to help portfolio companies to achieve strategic goals efficiently. The partners of the fund have combined decades of drug industry experiences before establishing the firm in 2019. The fund invests in true innovations with a major impact on patients’ lives. The firm’s investment size can range from $1 M and up to $6 M, in which the typical size would be $3 M~$4 M. The firm is actively looking for new investment opportunities in North America and Europe. The firm can act as lead or co-investor.
Within biotech, the firm focuses on companies in pre-IND to phase II. The firm is opportunistic in all indications and willing to consider orphan indications.
The firm has no specific requirements for companies. The firm generally takes a board seat or an observer seat.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply